Wuhan Hiteck Biological Pharma Co.,Ltd

SZSE:300683 Stock Report

Market Cap: CN¥3.5b

Wuhan Hiteck Biological PharmaLtd Balance Sheet Health

Financial Health criteria checks 4/6

Wuhan Hiteck Biological PharmaLtd has a total shareholder equity of CN¥2.5B and total debt of CN¥45.4M, which brings its debt-to-equity ratio to 1.8%. Its total assets and total liabilities are CN¥2.9B and CN¥490.1M respectively.

Key information

1.8%

Debt to equity ratio

CN¥45.37m

Debt

Interest coverage ration/a
CashCN¥877.57m
EquityCN¥2.45b
Total liabilitiesCN¥490.13m
Total assetsCN¥2.94b

Recent financial health updates

No updates

Recent updates

Wuhan Hiteck Biological Pharma Co.,Ltd's (SZSE:300683) Shareholders Might Be Looking For Exit

Oct 02
Wuhan Hiteck Biological Pharma Co.,Ltd's (SZSE:300683) Shareholders Might Be Looking For Exit

There's No Escaping Wuhan Hiteck Biological Pharma Co.,Ltd's (SZSE:300683) Muted Revenues Despite A 28% Share Price Rise

Mar 08
There's No Escaping Wuhan Hiteck Biological Pharma Co.,Ltd's (SZSE:300683) Muted Revenues Despite A 28% Share Price Rise

Financial Position Analysis

Short Term Liabilities: 300683's short term assets (CN¥1.3B) exceed its short term liabilities (CN¥327.6M).

Long Term Liabilities: 300683's short term assets (CN¥1.3B) exceed its long term liabilities (CN¥162.5M).


Debt to Equity History and Analysis

Debt Level: 300683 has more cash than its total debt.

Reducing Debt: 300683's debt to equity ratio has increased from 0% to 1.8% over the past 5 years.

Debt Coverage: 300683's debt is well covered by operating cash flow (169.4%).

Interest Coverage: Insufficient data to determine if 300683's interest payments on its debt are well covered by EBIT.


Balance Sheet


Discover healthy companies